• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Redx Pharma, Pierre Fabre Laboratories to collaborate on cancer research

Redx Pharma, Pierre Fabre Laboratories to collaborate on cancer research

March 7, 2014
CenterWatch Staff

Redx, a provider of translational research capacity and experience in cancer stem cells, tumor immunology and anti-microbial resistance, and Pierre Fabre Research Institute (IRPF) have formed an agreement for cancer research. The exclusive deal will see Redx and IRPF work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.

Financial terms have not been disclosed, but Redx Pharma chief executive Neil Murray described the deal as a highly significant milestone in the company's development.

The Redx Pharma group is focused on early stage drug discovery and development programs at sites in Liverpool (Redx Oncology) and at Alderley Park, Cheshire (Redx Anti-Infectives).

Pierre Fabre, a French pharmaceutical company, has experience in both oncology and dermatology. Its portfolio focuses on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas. The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.

Neil Murray, chief executive of Redx Pharma, said, “The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing